Drugs.com Clinical Trial ResultsOriginal article
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
RegulatorypositiveOCU410Positive
AI Analysis
Summary
Ocugen announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for OCU410 for the treatment of geographic atrophy secondary to dry age-related macular degeneration. This regulatory designation accelerates development of the gene therapy candidate.
Outcome Details
Regenerative Medicine Advanced Therapy (RMAT) Designation granted
Importance:7/10
Sentiment:
0.75
gene therapyblindnessFDA designationRMATophthalmologyage-related macular degeneration
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on July 29, 2026 2:08 AM